NASDAQ:PAVM PAVmed (PAVM) Stock Price, News & Analysis $1.51 -0.24 (-13.71%) Closing price 03:57 PM EasternExtended Trading$1.50 -0.01 (-0.33%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About PAVmed Stock (NASDAQ:PAVM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PAVmed alerts:Sign Up Key Stats Today's Range$1.45▼$1.7550-Day Range$1.34▼$4.5252-Week Range$1.17▼$28.44Volume38,984 shsAverage Volume24,005 shsMarket Capitalization$12.08 millionP/E RatioN/ADividend YieldN/APrice Target$56.00Consensus RatingHold Company Overview PAVmed Inc. is a medical technology company that develops and commercializes medical devices and diagnostic products. Its portfolio includes technologies aimed at addressing unmet needs in areas such as cancer detection, vascular access and minimally invasive procedures. Through its subsidiary Lucid Diagnostics, PAVmed is associated with EsoGuard, a molecular test designed to detect precancerous changes linked to esophageal cancer, and EsoCheck, a device used to collect cells from the esophagus. PAVmed has also developed PortIO, an intraosseous access device intended to provide a route for delivering fluids and medication. Founded in 2014, PAVmed is based in the United States and focuses primarily on developing technologies for the U.S. healthcare market.AI Generated. May Contain Errors. Read More PAVmed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScorePAVM MarketRank™: 2.0083709806 of 5 starsPAVmed scored higher than 40% of companies evaluated by MarketBeat, and ranked 660th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingPAVmed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialPAVmed has a consensus price target of $56.00, representing about 3,608.6% upside from its current price of $1.51.Amount of Analyst CoveragePAVmed has only been the subject of 1 research reports in the past 90 days.Read more about PAVmed's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for PAVmed are expected to decrease in the coming year, from ($3.80) to ($3.82) per share. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.19% of the float of PAVmed has been sold short.Short Interest Ratio / Days to CoverPAVmed has a short interest ratio ("days to cover") of 1.04, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PAVmed has recently increased by 0.75%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPAVmed does not currently pay a dividend.Dividend GrowthPAVmed does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.60 News SentimentPAVmed has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for PAVmed this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added PAVmed to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PAVmed insiders have not sold or bought any company stock.Percentage Held by Insiders13.40% of the stock of PAVmed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions19.93% of the stock of PAVmed is held by institutions.Read more about PAVmed's insider trading history. Receive PAVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PAVM Stock News HeadlinesPAVmed Earnings Call Highlights Lucid and Device ProgressNovember 15 at 8:19 AM | tipranks.comPAVmed Inc. Q3 2026 Earnings Call SummaryNovember 13, 2026 | finance.yahoo.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 17 at 1:00 AM | Behind the Markets (Ad)PAVmed (PAVM) Q3 2026 Earnings Call TranscriptNovember 13, 2026 | finance.yahoo.comTranscript : PAVmed Inc., Q3 2026 Earnings Call, Nov 13, 2026November 13, 2026 | marketscreener.comMPAVmed outlines early 2027 Veris 510(k) submission while Lucid secures Medicare reimbursement for EsoGuardNovember 13, 2026 | seekingalpha.comPAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial ResultsNovember 13, 2026 | prnewswire.comLucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial ResultsNovember 12, 2026 | prnewswire.comSee More Headlines PAVM Stock Analysis - Frequently Asked Questions How have PAVM shares performed this year? PAVmed's stock was trading at $7.33 on January 1st, 2026. Since then, PAVM stock has decreased by 79.4% and is now trading at $1.51. How were PAVmed's earnings last quarter? PAVmed Inc. (NASDAQ:PAVM) announced its earnings results on Thursday, May, 14th. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.69) by $0.48. The business earned $22 thousand during the quarter, compared to analysts' expectations of $74 thousand. PAVmed had a negative trailing twelve-month return on equity of 61.95% and a negative net margin of 12,406.76%. Read the conference call transcript. When did PAVmed's stock split? PAVmed shares reverse split on the morning of Friday, January 2nd 2026.The 1-30 reverse split was announced on Tuesday, December 30th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 31st 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of PAVmed? Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PAVmed own? Based on aggregate information from My MarketBeat watchlists, some other companies that PAVmed investors own include NIO (NIO), NVIDIA (NVDA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Plug Power (PLUG), Micron Technology (MU) and Block (XYZ). Company Calendar Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PAVM's financial health is in the Red zone, according to TradeSmith. PAVM has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:PAVM CIK1624326 Webwww.pavmed.com Phone(212) 949-4319FaxN/AEmployees41Year Founded2014Price Target and Rating Average Price Target for PAVmed$56.00 High Price Target$56.00 Low Price Target$56.00 Potential Upside/Downside+3,608.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($9.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$400 thousand Net Margins-12,406.76% Pretax Margin-14,669.64% Return on Equity-61.95% Return on Assets-17.08% Debt Debt-to-Equity Ratio0.98 Current Ratio1.19 Quick Ratio1.19 Sales & Book Value Annual Sales$70 thousand Price / Sales172.57 Cash FlowN/A Price / Cash FlowN/A Book Value($2.42) per share Price / Book-0.62Miscellaneous Outstanding Shares8,000,000Free Float6,925,000Market Cap$12.08 million OptionableNo Data Beta0.92 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:PAVM) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PAVmed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PAVmed With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.